We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-14.95%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.72B
AUM Growth
-$950M
Cap. Flow
-$368M
Cap. Flow %
-21.39%
Top 10 Hldgs %
48.56%
Holding
373
New
67
Increased
88
Reduced
111
Closed
78

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$59.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$32.9M
3
AMGN icon
Amgen
AMGN
+$18M
4
LLY icon
Eli Lilly
LLY
+$15.9M
5
BMY icon
Bristol-Myers Squibb
BMY
+$7.23M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$6.04M
2
ABT icon
Abbott
ABT
+$4.77M
3
RGNX icon
Regenxbio
RGNX
+$4.1M
4
CELG
Celgene Corp
CELG
+$3.94M
5
UTHR icon
United Therapeutics
UTHR
+$3.59M

Sector Composition

Rank Sector Weight
1 Healthcare 17.88%
2 Financials 0.23%
3 Consumer Staples 0.05%
4 Technology 0.03%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADYX
176
DELISTED
Adynxx Inc
ADYX
$649K 0.04%
18,340
-3,689
-17% -$154K
FOMX
177
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$648K 0.04%
58,338
-143,226
-71% -$1.35M
CSBR icon
178
Champions Oncology
CSBR
$76.4M
$641K 0.04%
253,504
-285,089
-53% -$555K
VTVT icon
179
vTv Therapeutics
VTVT
$123M
$640K 0.04%
3,314
-55
-2% -$12.6K
BCLI
180
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$637K 0.04%
16,718
-12,915
-44% -$448K
INSM icon
181
Insmed
INSM
$22.6B
$636K 0.04%
+48,043
New +$655K
SIEN
182
DELISTED
Sientra, Inc.
SIEN
$605K 0.04%
+7,097
New +$590K
OPGN
183
DELISTED
OpGen, Inc
OPGN
$604K 0.04%
5
-17
-77% -$2.11M
LJPC
184
PUT
DELISTED
La Jolla Pharmaceutical Company
LJPC
$589K 0.03%
+336
New +$6.44K
LUMO
185
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$579K 0.03%
6,254
+2,414
+63% +$272K
FOLD
186
PUT
DELISTED
Amicus Therapeutics
FOLD
$567K 0.03%
1,140
-1,142
-50% -$7.9K
GRDX
187
GridAI Technologies Corp
GRDX
$19.2M
$564K 0.03%
+1
New +$578K
MTFBW
188
DELISTED
Motif Bio plc Warrants to Purchase ADRs
MTFBW
$550K 0.03%
+426,170
New +$541K
SCON
189
DELISTED
Superconductor Technologies Inc.
SCON
$535K 0.03%
4,347
+1,842
+74% +$346K
BPMC
190
PUT
DELISTED
Blueprint Medicines
BPMC
$533K 0.03%
190
– –
HALO icon
191
PUT
Halozyme
HALO
$9.87B
$526K 0.03%
+532
New +$5.83K
SAGE
192
PUT
DELISTED
Sage Therapeutics
SAGE
$521K 0.03%
102
-163
-62% -$7.68K
ALNY icon
193
Alnylam Pharmaceuticals
ALNY
$38.5B
$518K 0.03%
+13,823
New +$579K
PCRX icon
194
PUT
Pacira BioSciences
PCRX
$1.05B
$514K 0.03%
159
– –
NDRM
195
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$511K 0.03%
+23,033
New +$431K
MNKD icon
196
PUT
MannKind Corp
MNKD
$1.2B
$499K 0.03%
1,568
-10,893
-87% -$31.5K
ABUS icon
197
CALL
Arbutus Biopharma
ABUS
$853M
$498K 0.03%
2,033
+84
+4% +$244
MRTX
198
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$474K 0.03%
99,735
– –
FLXN
199
PUT
DELISTED
Flexion Therapeutics, Inc.
FLXN
$472K 0.03%
248
+46
+23% +$879
SSKN
200
DELISTED
Strata Skin Sciences
SSKN
$455K 0.03%
20,696
+680
+3% +$17.4K
6 7
8
9 10

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2016 Portfolio in Review

As of Q4 2016, Sabby Management held 373 positions worth $1.72B, down 36% from $2.67B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sabby Management withdrew a net $368M in Q4 2016, closing 78 positions and reducing 111 holdings. Its most notable exit was Shire pic, an estimated $6.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 9.2% a quarter earlier, followed by Financials and Consumer Staples.

Against the trend, Sabby Management opened a new position in Eli Lilly worth $15.7M.

  • Sabby Management's largest Q4 2016 buy was Eli Lilly: 213,113 shares worth $15.7M.
  • Sabby Management added most to Sarepta Therapeutics in Q4 2016, an estimated $59.4M increase.
  • Sabby Management's biggest Q4 2016 reduction was Regenxbio, cutting an estimated $4.1M.
  • Sabby Management fully exited Shire pic in Q4 2016, selling an estimated $6.04M.
  • Sabby Management's ten largest holdings make up 49% of its $1.72B portfolio in Q4 2016.
  • Sabby Management opened 67 new positions and closed 78 in Q4 2016.
  • Sabby Management's portfolio value fell 36% quarter-over-quarter to $1.72B.

Based on Sabby Management's 13F filing for Q4 2016, filed 14 Feb 2017.